JP2005530486A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005530486A5 JP2005530486A5 JP2003571297A JP2003571297A JP2005530486A5 JP 2005530486 A5 JP2005530486 A5 JP 2005530486A5 JP 2003571297 A JP2003571297 A JP 2003571297A JP 2003571297 A JP2003571297 A JP 2003571297A JP 2005530486 A5 JP2005530486 A5 JP 2005530486A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotides
- pharmaceutical composition
- oligonucleotide
- trpm
- tumor cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/080,794 US6900187B2 (en) | 1999-02-26 | 2002-02-22 | TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications |
| PCT/US2003/005305 WO2003072591A1 (en) | 2002-02-22 | 2003-02-20 | Trpm-2 antisense therapy using an oligonucleotide having 2'-o-(2-methoxyl)ethyl modifications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005530486A JP2005530486A (ja) | 2005-10-13 |
| JP2005530486A5 true JP2005530486A5 (https=) | 2006-04-06 |
Family
ID=27765243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003571297A Abandoned JP2005530486A (ja) | 2002-02-22 | 2003-02-20 | ２’−ｏ−（２−メトキシ）エチル修飾を有するオリゴヌクレオチドを使用するｔｒｐｍ−２アンチセンス療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6900187B2 (https=) |
| EP (1) | EP1485401A4 (https=) |
| JP (1) | JP2005530486A (https=) |
| KR (1) | KR20040088514A (https=) |
| AU (1) | AU2003213190A1 (https=) |
| CA (1) | CA2475433A1 (https=) |
| HU (1) | HUP0500041A3 (https=) |
| NO (1) | NO20043953L (https=) |
| NZ (1) | NZ534490A (https=) |
| WO (1) | WO2003072591A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4785252B2 (ja) | 1999-02-26 | 2011-10-05 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | Ｔｒｐｍ−２アンチセンス療法 |
| US6900187B2 (en) | 1999-02-26 | 2005-05-31 | The University Of British Columbia | TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications |
| US7569551B2 (en) * | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
| WO2003062421A1 (en) * | 2002-01-17 | 2003-07-31 | The University Of British Columbia | Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
| SI1530636T1 (sl) * | 2002-08-21 | 2010-12-31 | Stry Liaison Ofiice The University Of British Columbia Umiversity Indu | Zdravljenje melanoma z zniĹľanjem nivojev klusterina |
| AU2003298921A1 (en) * | 2002-12-04 | 2004-06-23 | Algos Therapeutics, Inc. | Methods and materials for modulating trpm2 |
| US20040220131A1 (en) * | 2003-04-18 | 2004-11-04 | The University Of British Columbia | Method for treatment of cancerous angiogenic disorders |
| US20050053981A1 (en) * | 2003-09-09 | 2005-03-10 | Swayze Eric E. | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini |
| US8710020B2 (en) * | 2004-04-02 | 2014-04-29 | The University Of British Columbia | Clusterin antisense therapy for treatment of cancer |
| US8815599B2 (en) | 2004-06-01 | 2014-08-26 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
| US7919472B2 (en) * | 2004-09-17 | 2011-04-05 | Isis Pharmaceuticals, Inc. | Enhanced antisense oligonucleotides |
| CA2584646C (en) * | 2004-11-23 | 2015-11-03 | The University Of British Columbia | Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels |
| ES2543341T3 (es) | 2005-09-13 | 2015-08-18 | National Research Council Of Canada | Métodos y composiciones para modular la actividad de células tumorales |
| KR20080065617A (ko) * | 2005-09-19 | 2008-07-14 | 존슨 앤드 존슨 파머슈티컬 리서치 앤드 디벨로프먼트 엘엘씨 | 글루코코티코이드 수용체 발현의 조절 |
| ES2548240T3 (es) * | 2005-12-01 | 2015-10-15 | Pronai Therapeutics, Inc. | Terapias para el cáncer y composiciones farmacéuticas usadas en las mismas |
| PL1957044T3 (pl) | 2005-12-01 | 2013-11-29 | Pronai Therapeutics Inc | Amfoteryczny preparat liposomowy |
| NZ589262A (en) * | 2008-07-18 | 2012-05-25 | Oncogenex Technologies Inc | Antisense formulation |
| ES2657214T3 (es) * | 2008-07-30 | 2018-03-02 | Nitto Denko Corporation | Vehículos de fármacos |
| WO2011005779A2 (en) | 2009-07-07 | 2011-01-13 | University Of Southern California | Biomarkers for the early detection of autoimmune diseases |
| EA034462B1 (ru) | 2009-11-24 | 2020-02-11 | Алетиа Байотерапьютикс Инк. | Антикластериновые антитела и антигенсвязывающие фрагменты и их использование для уменьшения объема новообразований |
| SG192957A1 (en) * | 2011-03-15 | 2013-09-30 | Univ British Columbia | Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer |
| AU2012328680A1 (en) | 2011-10-25 | 2014-05-01 | Ionis Pharmaceuticals, Inc. | Antisense modulation of GCCR expression |
| US9822170B2 (en) | 2012-02-22 | 2017-11-21 | Alethia Biotherapeutics Inc. | Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer |
| LT2841578T (lt) * | 2012-04-23 | 2017-09-25 | Biomarin Technologies B.V. | Rnr moduliuojantys oligonukleotidai su pagerintomis savybėmis, skirti neuromuskulinių susirgimų gydymui |
| UY34812A (es) * | 2012-05-18 | 2013-12-31 | Teva Pharma | Método para el tratamiento del cáncer de pulmón de células no pequeñas |
| US10024844B2 (en) | 2012-12-20 | 2018-07-17 | Hospital For Special Surgery | Identification of an inhibitor of iRhom1 or an inhibitor of iRhom2 |
| WO2015048531A1 (en) | 2013-09-26 | 2015-04-02 | Beth Israel Deaconess Medical Center, Inc. | Inhibition of sgk1 in the treatment of heart conditions |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5789389A (en) * | 1995-03-17 | 1998-08-04 | Board Of Trustees Of University Of Illinois | BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs |
| US6383808B1 (en) * | 2000-09-11 | 2002-05-07 | Isis Pharmaceuticals, Inc. | Antisense inhibition of clusterin expression |
| JPH11143729A (ja) * | 1997-11-07 | 1999-05-28 | Nec Corp | フォールトトレラントコンピュータ |
| US6335194B1 (en) | 1998-09-29 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Antisense modulation of survivin expression |
| US6172216B1 (en) * | 1998-10-07 | 2001-01-09 | Isis Pharmaceuticals Inc. | Antisense modulation of BCL-X expression |
| US6900187B2 (en) | 1999-02-26 | 2005-05-31 | The University Of British Columbia | TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications |
| JP4785252B2 (ja) | 1999-02-26 | 2011-10-05 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | Ｔｒｐｍ−２アンチセンス療法 |
| CA2393646A1 (en) | 1999-12-21 | 2001-06-28 | Yale University | Survivin promotion of angiogenesis |
| US20020132350A1 (en) | 2000-09-14 | 2002-09-19 | Pioneer Hi-Bred International, Inc. | Targeted genetic manipulation using Mu bacteriophage cleaved donor complex |
| WO2003062421A1 (en) | 2002-01-17 | 2003-07-31 | The University Of British Columbia | Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
-
2002
- 2002-02-22 US US10/080,794 patent/US6900187B2/en not_active Expired - Fee Related
-
2003
- 2003-02-20 HU HU0500041A patent/HUP0500041A3/hu unknown
- 2003-02-20 EP EP03709236A patent/EP1485401A4/en not_active Withdrawn
- 2003-02-20 WO PCT/US2003/005305 patent/WO2003072591A1/en not_active Ceased
- 2003-02-20 AU AU2003213190A patent/AU2003213190A1/en not_active Abandoned
- 2003-02-20 KR KR10-2004-7013102A patent/KR20040088514A/ko not_active Withdrawn
- 2003-02-20 NZ NZ534490A patent/NZ534490A/en unknown
- 2003-02-20 JP JP2003571297A patent/JP2005530486A/ja not_active Abandoned
- 2003-02-20 CA CA002475433A patent/CA2475433A1/en not_active Abandoned
-
2004
- 2004-09-21 NO NO20043953A patent/NO20043953L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005530486A5 (https=) | ||
| US9200285B2 (en) | Clusterin antisense therapy for treatment of cancer | |
| JP4785252B2 (ja) | Ｔｒｐｍ−２アンチセンス療法 | |
| JP2003503309A5 (https=) | ||
| US5744460A (en) | Combination for treatment of proliferative diseases | |
| US7795232B1 (en) | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers | |
| Nuno Moreira et al. | Bcl-2-targeted antisense therapy (Oblimersen sodium): towards clinical reality | |
| AU2001288373A1 (en) | Methods of treatment of a BCL-2 disorder using BCL-2 antisense oligomers | |
| JP2018530325A (ja) | アンジオテンシノーゲンの発現を調節するための化合物及び方法 | |
| JP2015523853A (ja) | Ａｔｐ２ａ２発現を調節するための組成物及び方法 | |
| JP2015518712A (ja) | Ｍｅｃｐ２発現を調節するための組成物及び方法 | |
| US6080727A (en) | Oligonucleotide treatments and compositions for human melanoma | |
| KR101052289B1 (ko) | 클러스테린 양의 감소에 의한 흑색종의 치료 | |
| JP2006502243A5 (https=) | ||
| JP2006503904A5 (https=) | ||
| CN115176008A (zh) | 用于抑制FoxP3表达的修饰反义寡核苷酸 | |
| JPH11511965A (ja) | ヒトｍｄｒ１およびｍｒｐ遺伝子を標的とする治療用オリゴヌクレオチド | |
| JP5406024B2 (ja) | Ｂｃｌ−ＸＬ特異的ｓｉＮＡを用いる癌治療法 | |
| CA2421087A1 (en) | Antisense insulin-like growth factor binding protein (igfbp)-2 oligodeoxynucleotides for prostate and other endocrine tumor therapy | |
| WO2004056971A2 (en) | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers | |
| Benner et al. | Combination of antisense oligonucleotide and low-dose chemotherapy in hematological malignancies | |
| Nakamura et al. | Antisense oligonucleotide for tissue factor inhibits hepatic ischemic reperfusion injury | |
| JP7766375B2 (ja) | 変形されたｒｔ－ｌｅｔ７を有効成分として含む肝癌の予防または治療用組成物 | |
| Yacyshyn et al. | Making sense of antisense | |
| US20050032714A1 (en) | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |